SBIR/STTR Research Award

Release Chondroitinase Systems for Spinal Cord Injury

Award identifier 4db5081fe593c4005436537b2a8515068a76e834ed6550b8526fe19eb41a5e73Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$107,300

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Acorda Therapeutics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
R5D3FUPFFPK4
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and causes a severe and debilitating condition in the individual. Following SCI, limited regeneration of injured neurons results in permanent disability characterized by some loss of sensation, paralysis and autonomic dysfunction. One reason that neurons fail to regenerate is their inability to traverse the glial scar that develops following SCI. This glial scar contains extra cellular matrix molecules including chondroitin sulfate proteoglycans (CSPGs). In vitro studies show that neurons fail to extend processes over CSPG coated surfaces, while in vivo data correlate failure of regeneration with areas of CSPG expression. Treatment with bacterial chondroitinase (Chase), an enzyme that digests CSPG arbohydrate chains, decreases the CSPG inhibition, both in vitro and in vivo. Chase was recently used to treat spinal cord lesions in a rodent model, resulting in enhanced functional recovery. Several obstacles exist in the development of a Chase-based SCI therapy, including the delivery of a large protein to the central nervous system and the use of an enzyme with a short half-life in solution at body temperature. The aim of this study is to develop a sustained release (SR) formulation of a Chase therapy that can be delivered locally to the site of injury and demonstrate its effectiveness at digesting CSPGs in the rat spinal cord. To accomplish these goals are a repertoire of Chase enzymes will be cloned, expressed and purified. These enzymes will then be tested in vitro in several existing sustained release formulations. These sustained release Chase formulations will then be place in the sub-dural space of rat spinal cords to assess their ability to digest CSPGs in vivo. These studies will provide justification for a Phase II study examining the therapeutic effects of sustained release formulation of chondroitinase in an animal model of spinal cord injury.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

10 SBIR/STTR records share this UEI (1996–2005). Reported award amounts total $2,216,009. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.